- Home
- OBIO vs ZNTL Comparison
OBIO vs ZNTL Comparison
Compare OBIO & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OBIO | ZNTL |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.2M | 118.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OBIO | ZNTL |
|---|---|---|
| Price | $4.87 | $2.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $14.00 | $5.87 |
| AVG Volume (30 Days) | 209.4K | ★ 1.4M |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,818,000.00 | ★ $26,865,000.00 |
| Revenue This Year | $35.75 | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $2.20 | $1.01 |
| 52 Week High | $6.16 | $3.19 |
Technical Indicators
Market Signals| Indicator | OBIO | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 63.28 | 90.72 |
| Support Level | $4.05 | $1.31 |
| Resistance Level | $4.37 | $1.46 |
| Average True Range (ATR) | 0.26 | 0.20 |
| MACD | 0.04 | 0.14 |
| Stochastic Oscillator | 95.70 | 86.29 |
Price Performance
Historical ComparisonAbout OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.